These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 23089529)
61. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS Registry. Maier B; Hegenbarth C; Theres H; Schoeller R; Schuehlen H; Behrens S; Cardiol J; 2014; 21(5):465-73. PubMed ID: 24142683 [TBL] [Abstract][Full Text] [Related]
62. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531 [TBL] [Abstract][Full Text] [Related]
63. Interventional cardiology: does an optimal antithrombotic regimen for PCI exist? Lincoff AM Nat Rev Cardiol; 2014 Jan; 11(1):10-2. PubMed ID: 24302216 [No Abstract] [Full Text] [Related]
64. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Capodanno D; Angiolillo DJ Circ Cardiovasc Interv; 2014 Feb; 7(1):113-24. PubMed ID: 24550531 [No Abstract] [Full Text] [Related]
65. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853 [TBL] [Abstract][Full Text] [Related]
66. Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome. Alraies MC; Lee SY; Lipinski MJ; Buchanan K; Steinvil A; Rogers T; Koifman E; Gai J; Torguson R; Ben-Dor I; Satler LF; Pichard AD; Waksman R Am J Cardiol; 2017 Oct; 120(8):1272-1278. PubMed ID: 28826893 [TBL] [Abstract][Full Text] [Related]
67. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen JK; Cuisset T; Kirchhof P; Marín F; Eur Heart J; 2010 Jun; 31(11):1311-8. PubMed ID: 20447945 [TBL] [Abstract][Full Text] [Related]
79. [Optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting: the real question nowadays is...]. Rubboli A; Ricci Lucchi G; Vecchio S G Ital Cardiol (Rome); 2019 Jun; 20(6):396. PubMed ID: 31184327 [No Abstract] [Full Text] [Related]
80. The role of percutaneous coronary intervention in managing patients with stable ischemic heart disease. Herbert T; Rizzolo D JAAPA; 2020 Jun; 33(6):18-22. PubMed ID: 32384294 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]